Diabetes screening intervals based on risk stratification.

<h4>Background</h4> <p>Guidelines for frequency of Type 2 diabetes mellitus (DM) screening remain unclear, with proposed screening intervals typically based on expert opinion. This study aims to demonstrate that HbA1c screening intervals may differ substantially when considering i...

Full description

Bibliographic Details
Main Authors: Ohde, S, McFadden, E, Deshpande, G, Yokomichi, H, Takahashi, O, Fukui, T, Perera, R, Yamagata, Z
Format: Journal article
Language:English
Published: Biomed Central 2016
_version_ 1797080126576394240
author Ohde, S
McFadden, E
Deshpande, G
Yokomichi, H
Takahashi, O
Fukui, T
Perera, R
Yamagata, Z
author_facet Ohde, S
McFadden, E
Deshpande, G
Yokomichi, H
Takahashi, O
Fukui, T
Perera, R
Yamagata, Z
author_sort Ohde, S
collection OXFORD
description <h4>Background</h4> <p>Guidelines for frequency of Type 2 diabetes mellitus (DM) screening remain unclear, with proposed screening intervals typically based on expert opinion. This study aims to demonstrate that HbA1c screening intervals may differ substantially when considering individual risk for diabetes.</p> <h4>Methods</h4> <p>This was a multi-institutional retrospective open cohort study. Data were collected between April 1999 to March 2014 from one urban and one rural cohort in Japan. After categorization by age, we stratified individuals based on cardiovascular disease risk (Framingham 10-year cardiovascular risk score) and body mass index (BMI). We adapted a signal-to-noise method for distinguishing true HbA1c change from measurement error by constructing a linear random effect model to calculate signal and noise of HbA1c. Screening interval for HbA1c was defined as informative when the signal-to-noise ratio exceeded 1.</p> <h4>Results</h4> <p>Among 96,456 healthy adults, 46,284 (48.0%) were male; age (range) and mean HbA1c (SD) were 48 (30–74) years old and 5.4 (0.4)%, respectively. As risk increased among those 30–44 years old, HbA1c screening intervals for detecting Type 2 DM consistently decreased: from 10.5 (BMI &lt;18.5) to 2.4 (BMI &gt; 30) years, and from 8.0 (Framingham Risk Score &lt;10%) to 2.0 (Framingham Risk Score ≥20%) years. This trend was consistent in other age and risk groups as well; among obese 30–44 year olds, we found substantially shorter intervals compared to other groups.</p> <h4>Conclusions</h4> <p>HbA1c screening intervals for identification of DM vary substantially by risk factors. Risk stratification should be applied when deciding an optimal HbA1c screening interval in the general population to minimize overdiagnosis and overtreatment.</p>
first_indexed 2024-03-07T00:55:43Z
format Journal article
id oxford-uuid:880272a3-1dbc-4a9f-b81e-551331950e09
institution University of Oxford
language English
last_indexed 2024-03-07T00:55:43Z
publishDate 2016
publisher Biomed Central
record_format dspace
spelling oxford-uuid:880272a3-1dbc-4a9f-b81e-551331950e092022-03-26T22:14:12ZDiabetes screening intervals based on risk stratification.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:880272a3-1dbc-4a9f-b81e-551331950e09EnglishSymplectic Elements at OxfordBiomed Central2016Ohde, SMcFadden, EDeshpande, GYokomichi, HTakahashi, OFukui, TPerera, RYamagata, Z <h4>Background</h4> <p>Guidelines for frequency of Type 2 diabetes mellitus (DM) screening remain unclear, with proposed screening intervals typically based on expert opinion. This study aims to demonstrate that HbA1c screening intervals may differ substantially when considering individual risk for diabetes.</p> <h4>Methods</h4> <p>This was a multi-institutional retrospective open cohort study. Data were collected between April 1999 to March 2014 from one urban and one rural cohort in Japan. After categorization by age, we stratified individuals based on cardiovascular disease risk (Framingham 10-year cardiovascular risk score) and body mass index (BMI). We adapted a signal-to-noise method for distinguishing true HbA1c change from measurement error by constructing a linear random effect model to calculate signal and noise of HbA1c. Screening interval for HbA1c was defined as informative when the signal-to-noise ratio exceeded 1.</p> <h4>Results</h4> <p>Among 96,456 healthy adults, 46,284 (48.0%) were male; age (range) and mean HbA1c (SD) were 48 (30–74) years old and 5.4 (0.4)%, respectively. As risk increased among those 30–44 years old, HbA1c screening intervals for detecting Type 2 DM consistently decreased: from 10.5 (BMI &lt;18.5) to 2.4 (BMI &gt; 30) years, and from 8.0 (Framingham Risk Score &lt;10%) to 2.0 (Framingham Risk Score ≥20%) years. This trend was consistent in other age and risk groups as well; among obese 30–44 year olds, we found substantially shorter intervals compared to other groups.</p> <h4>Conclusions</h4> <p>HbA1c screening intervals for identification of DM vary substantially by risk factors. Risk stratification should be applied when deciding an optimal HbA1c screening interval in the general population to minimize overdiagnosis and overtreatment.</p>
spellingShingle Ohde, S
McFadden, E
Deshpande, G
Yokomichi, H
Takahashi, O
Fukui, T
Perera, R
Yamagata, Z
Diabetes screening intervals based on risk stratification.
title Diabetes screening intervals based on risk stratification.
title_full Diabetes screening intervals based on risk stratification.
title_fullStr Diabetes screening intervals based on risk stratification.
title_full_unstemmed Diabetes screening intervals based on risk stratification.
title_short Diabetes screening intervals based on risk stratification.
title_sort diabetes screening intervals based on risk stratification
work_keys_str_mv AT ohdes diabetesscreeningintervalsbasedonriskstratification
AT mcfaddene diabetesscreeningintervalsbasedonriskstratification
AT deshpandeg diabetesscreeningintervalsbasedonriskstratification
AT yokomichih diabetesscreeningintervalsbasedonriskstratification
AT takahashio diabetesscreeningintervalsbasedonriskstratification
AT fukuit diabetesscreeningintervalsbasedonriskstratification
AT pererar diabetesscreeningintervalsbasedonriskstratification
AT yamagataz diabetesscreeningintervalsbasedonriskstratification